480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12Shawn M. Jensen, Bernard A. Fox, Christopher G. Twitty et al.|Regular and Young Investigator Award Abstracts|2020Cited by 5
Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trialRom S. Leidner, Bernard A. Fox, Ryan Meng et al.|Cancer Research|2024Cited by 3
148 Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccineRyan Meng, Bernard A. Fox, Tarsem Moudgil et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1
1481 Off-the-shelf dark matter immunotherapy in head & neck cancer: mechanistic insights and clinical efficacyRom S. Leidner, Bernard A. Fox, Christopher Paustian et al.|Unknown|2024Cited by 1
113 Uncovering the dark immunopeptidome of head and neck squamous cell carcinoma (HNSCC): relevance for universal cancer vaccines, immunological monitoring and TIL therapyNoriko Iwamoto, Bernard A. Fox, Takashi Shimada et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1